Real-World Treatment Patterns and Clinical Outcomes in Age-Related Macular Degeneration: Insights from Clinical Practice
This special issue belongs to the section "Retinal Function and Disease".
Special Issue Information
Dear Colleagues,
Age-related macular degeneration (AMD) remains a leading cause of visual impairment globally, encompassing both neovascular (nAMD) and non-neovascular (dry) forms of the disease. While anti-vascular endothelial growth factor (anti-VEGF) therapies have transformed the management of nAMD, outcomes in real-world settings often differ from those reported in clinical trials due to variability in treatment regimens, patient characteristics, and healthcare delivery. Meanwhile, the management of dry AMD continues to evolve, with growing interest in observational data, risk modification, and emerging therapeutic strategies.
This Special Issue aims to explore real-world evidence across the full spectrum of AMD. We welcome contributions evaluating different treatment approaches for nAMD, including treat-and-extend (T&E), pro re nata (PRN), and fixed dosing regimens, as well as comparisons between anti-VEGF agents and the role of adjunctive therapies. Studies examining treatment-naïve and treatment-refractory populations, injection burden, durability, and long-term outcomes are particularly encouraged.
A key focus will be on the role of imaging, particularly optical coherence tomography (OCT), in guiding clinical decision-making. Submissions investigating imaging biomarkers, predictors of treatment response, and disease activity are highly welcomed. We also encourage studies addressing the heterogeneity of AMD, including distinct clinical subtypes such as polypoidal choroidal vasculopathy (PCV), and how these influence treatment strategies.
Importantly, this Special Issue seeks to highlight real-world challenges in delivering care, including healthcare disparities, underserved populations, and structural barriers to treatment adherence. Variations in access to care, treatment intensity, and follow-up may disproportionately affect those with the greatest clinical need, and we welcome contributions exploring these dynamics across diverse patient populations, socioeconomic backgrounds, and healthcare systems.
By bringing together evidence from observational studies, registries, and routine clinical practice, this Special Issue aims to bridge the gap between clinical trials and real-world care, supporting more personalised, equitable, and effective management of AMD.
Dr. Yu Jeat Chong
Dr. Niro N. Narendran
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vision is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neovascular age-related macular degeneration (nAMD)
- dry age-related macular degeneration
- real-world evidence
- anti-VEGF therapy
- treatment regimens (treat-and-extend, PRN)
- optical coherence tomography (OCT) biomarkers
- treatment-naïve and refractory disease
- polypoidal choroidal vasculopathy (PCV)
- healthcare disparities and access to care
- personalised treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

